GlassScriptPhysician profile
Julie Thomas
NPI 1174856447
$5,363.68
in general payments reported to CMS, 2019-2025
11 companies · $931 in 2025
The $931 reported for 2025 was more than what 82% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $452 · 2022: $1,341 · 2023: $907 · 2024: $1,732 · 2025: $931.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,560 · Education: $10.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,560.31 |
| Education | $10.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,733.87 | 2021-2025 | |
| Janssen Biotech, INC. | $1,116.40 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Genzyme Corporation | $507.67 | 2022-2025 | |
| Gilead Sciences, INC. | $257.20 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $214.57 | 2022-2024 | Zeposia, Eliquis |
| Regeneron Healthcare Solutions, INC. | $203.34 | 2022-2024 | Dupixent |
| Braintree Laboratories, INC. | $116.47 | 2021-2022 | |
| Celgene Corporation | $103.45 | 2021-2022 | |
| Ardelyx, INC. | $38.01 | 2022-2023 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $37.95 | 2024 | Entyvio |
| Janssen Pharmaceuticals, INC | $34.75 | 2024-2025 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.